idera pharmaceuticals is a clinical stage biotechnology company with expertise in discovering, developing and commercializing novel nucleic acid therapeutics to treat patients with serious and life-threatening diseases. idera is focused on harnessing the potential of our proprietary technology to treat genetically defined forms of b-cell lymphomas and rare autoimmune diseases.
Company profile
Ticker
ACGN
Exchange
Website
CEO
Vincent Milano
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Ginkgo Bioworks • Exelixis • Acorda Therapeutics ...
Former names
HYBRIDON INC, IDERA PHARMACEUTICALS, INC.
SEC CIK
Corporate docs
IRS number
43072298
ACGN stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
28 Aug 23
EFFECT
Notice of effectiveness
18 Aug 23
EFFECT
Notice of effectiveness
18 Aug 23
EFFECT
Notice of effectiveness
18 Aug 23
EFFECT
Notice of effectiveness
18 Aug 23
EFFECT
Notice of effectiveness
18 Aug 23
EFFECT
Notice of effectiveness
18 Aug 23
EFFECT
Notice of effectiveness
18 Aug 23
EFFECT
Notice of effectiveness
18 Aug 23
EFFECT
Notice of effectiveness
18 Aug 23
Transcripts
Latest ownership filings
4
MAXINE GOWEN
11 Aug 23
4
VINCENT MILANO
11 Aug 23
144
Notice of proposed sale of securities
10 Aug 23
144
Notice of proposed sale of securities
10 Aug 23
SC 13D/A
Pillar Pharmaceuticals 6, L.P.
3 Aug 23
144
Notice of proposed sale of securities
25 Jul 23
4
YOUSSEF EL ZEIN
19 Jul 23
4
YOUSSEF EL ZEIN
19 Jul 23
3/A
YOUSSEF EL ZEIN
19 Jul 23
SC 13D/A
Pillar Pharmaceuticals 6, L.P.
17 Jul 23
Financial summary
| Quarter (USD) | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 2.12 mm | 2.12 mm | 2.12 mm | 2.12 mm | 2.12 mm | 2.12 mm |
| Cash burn (monthly) | 3.31 mm | 2.16 mm | 7.38 mm | 3.99 mm | 3.28 mm | 2.48 mm |
| Cash used (since last report) | 19.42 mm | 12.65 mm | 43.31 mm | 23.42 mm | 19.27 mm | 14.56 mm |
| Cash remaining | -17.30 mm | -10.53 mm | -41.19 mm | -21.30 mm | -17.15 mm | -12.44 mm |
| Runway (months of cash) | -5.2 | -4.9 | -5.6 | -5.3 | -5.2 | -5.0 |
Institutional ownership, Q2 2023
14.8% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 21 |
| Opened positions | 1 |
| Closed positions | 1 |
| Increased positions | 5 |
| Reduced positions | 4 |
| 13F shares | Current |
|---|---|
| Total value | 269.48 mm |
| Total shares | 1.25 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Pillar Pharmaceuticals 6 | 806.41 k | $0.00 |
| Castellina Ventures | 277.00 k | $0.00 |
| Vanguard | 74.17 k | $120.90 mm |
| BLK Blackrock | 25.21 k | $41.10 mm |
| Geode Capital Management | 23.34 k | $38.05 mm |
| STT State Street | 11.65 k | $18.99 mm |
| Credit Agricole S A | 11.52 k | $18.78 mm |
| Tower Research Capital | 7.13 k | $11.62 mm |
| MS Morgan Stanley | 4.86 k | $7.92 mm |
| Hollencrest Capital Management | 4.00 k | $6.52 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 10 Aug 23 | Milano Vincent | Common Stock | Sell | Dispose S | No | No | 0.5331 | 3,283 | 1.75 k | 8,987 |
| 10 Aug 23 | Maxine Gowen | Common Stock | Sell | Dispose S | Yes | No | 0.51 | 51 | 26.01 | 0 |
| 13 Jul 23 | Pillar Invest | Common Stock | Sell | Dispose S | Yes | No | 1.54 | 2,213 | 3.41 k | 164,894 |
| 12 Jul 23 | Pillar Invest | Common Stock | Sell | Dispose S | Yes | No | 1.58 | 3,605 | 5.70 k | 167,107 |
| 17 May 23 | Pillar Invest | Common Stock | Buy | Acquire P | Yes | No | 1.42 | 26,965 | 38.29 k | 170,712 |
News
12 Health Care Stocks Moving In Wednesday's After-Market Session
9 Aug 23
12 Health Care Stocks Moving In Monday's Intraday Session
7 Aug 23
Why Krystal Biotech Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
7 Aug 23
Why Aceragen (ACGN) Stock Is Down 30% Today
7 Aug 23
12 Health Care Stocks Moving In Monday's Pre-Market Session
7 Aug 23